Compare BIO-TECHNE Corp (TECH) vs Verizon Communications Inc (VZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Verizon Communications Inc — how do they compare? BIO-TECHNE Corp trades at $72.39 (market cap $11.34B), while Verizon Communications Inc trades at $49.79 (market cap $209.44B). The key difference: Verizon Communications Inc is far larger — about 18.5× BIO-TECHNE Corp's market cap, and Verizon Communications Inc pays the higher dividend (5.61%). Which is the better fit depends on your goals.
| TECH | VZ | |
|---|---|---|
Market Cap | $11.34B | $209.44B |
Sector | Health | Media |
52-Week High | $72.48 | $51.38 |
52-Week Low | $43.31 | $38.40 |
Enterprise Value | $11.36B | $396.15B |
Dividend Yield | 0.44% | 5.61% |
Volume | — | 22,584,735 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Verizon (VZ) trades at $50.41, up 0.54% today, with a bullish technical signal and consistent earnings beats in recent quarters. The stock offers a 5%+ dividend yield, supported by strong cash flow and a P/E of 13.13. Recent news highlights growth in broadband and AI infrastructure, including a multi-billion dollar fiber deal with Corning.
Outlook is positive with cost discipline and shareholder returns, but risks include high debt and competitive pressures. Analysts are mixed with a $49.69 consensus target, slightly below current price, indicating cautious optimism amid execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
